These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37529461)

  • 41. Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer.
    Huang Y; Wang J; Hu Y; Cao P; Wang G; Cai H; Wang M; Yang X; Wei Z; Ye X
    Front Oncol; 2022; 12():938827. PubMed ID: 36091128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study.
    Jiang FE; Zhang HJ; Yu CY; Liu AN
    Neoplasma; 2021 Jul; 68(4):861-866. PubMed ID: 33998237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
    Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
    World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab.
    Ye W; Cai L; Zhang M; Wu Y; Sun H; Wang YD; Xia Y
    Front Immunol; 2023; 14():1221418. PubMed ID: 37575222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis.
    Tang Q; Wu D; Huang H; Fang H; Wu Y; Liu F; Li N
    Front Pharmacol; 2023; 14():1093194. PubMed ID: 37180706
    [No Abstract]   [Full Text] [Related]  

  • 47. Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report.
    Yu Q; Wang WX
    World J Clin Cases; 2020 Feb; 8(3):624-629. PubMed ID: 32110675
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma.
    Song Y; Wu J; Chen X; Lin T; Cao J; Liu Y; Zhao Y; Jin J; Huang H; Hu J; Luo J; Zhang L; Xue H; Zhang Q; Wang W; Chen C; Feng J; Zhu J
    Clin Cancer Res; 2019 Dec; 25(24):7363-7369. PubMed ID: 31420358
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial.
    Lei J; Zhao J; Gong L; Ni Y; Zhou Y; Tian F; Liu H; Gu Z; Huang L; Lu Q; Wang X; Sun J; Yang E; Wang T; Zhong D; Wang J; Zhao Z; Liu Z; Wang C; Wang X; Lei G; Yan X; Jiang T
    JAMA Oncol; 2023 Oct; 9(10):1348-1355. PubMed ID: 37535377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Meta-analysis on safety of Tripterygium Glycosides Tablets in treatment of rheumatoid arthritis].
    Li YQ; Hu RX; Jia KX; Wang JX; Xu TT; Cui RZ; Ming RR; Li TX; Liu CF; Liao X; Lin N
    Zhongguo Zhong Yao Za Zhi; 2020 Feb; 45(4):775-790. PubMed ID: 32237477
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Camrelizumab-induced anaphylactic reaction: a case report and literature review.
    Hu J; Fan J; Qu S; He X; Liu D; Wang Y; Wu X; Li Z
    J Chemother; 2024 Jun; ():1-7. PubMed ID: 38937985
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study.
    Hou X; Zhou C; Wu G; Lin W; Xie Z; Zhang H; Yi J; Peng Z; Yin L; Ma C; Chen L
    J Thorac Oncol; 2023 Jun; 18(6):769-779. PubMed ID: 36738928
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
    Pu X; Wang Q; Liu L; Chen B; Li K; Zhou Y; Sheng Z; Liu P; Tang Y; Xu L; Li J; Kong Y; Xu F; Xu Y; Wu L
    Cancer Med; 2023 Apr; 12(7):7724-7733. PubMed ID: 36494905
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer.
    Lin Z; Cai M; Zhang P; Li G; Liu T; Li X; Cai K; Nie X; Wang J; Liu J; Liu H; Zhang W; Gao J; Wu C; Wang L; Fan J; Zhang L; Wang Z; Hou Z; Ma C; Yang K; Wu G; Tao K; Zhang T
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725214
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
    Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
    Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cutaneous adverse events associated with PD-1 inhibitor-based therapy in patients with non-small-cell lung cancer.
    Dang YC; Liu HB; Wang Z; Zhou YL; Chen J; Kong QT; Sang H
    Future Oncol; 2022 Dec; ():. PubMed ID: 36519587
    [No Abstract]   [Full Text] [Related]  

  • 57. Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study.
    Wu J; Song Y; Chen X; Lin T; Cao J; Liu Y; Zhao Y; Jin J; Huang H; Hu J; Luo J; Zhang L; Xue H; Zhang Q; Wang W; Chen C; Feng J; Zhu J
    Int J Cancer; 2022 Mar; 150(6):984-992. PubMed ID: 34674396
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatic cavernous hemangioma developed in non-small cell lung cancer patients after receiving Camrelizumab treatment: two case reports.
    Jin Y; Xu J; Zhuang D; Dong L; Sun Y; Zhao L; Xiao W
    Front Oncol; 2023; 13():1221309. PubMed ID: 37601678
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV).
    Xu CR; Chen Q; Zhou C; Wu L; Li W; Zhang H; Li Y; Xu F; Xiong J; Wang Q; Zhang H; Jiang Y; Yin H; Wu Q; Dai Q; Hu J; Chen J; Zhang J; Wu G; Yin J; Zhao J; Liu B; Shan J; Sheng L; Chen Q; Han Z; Shi H; Liu Y; Chen J; Wu YL
    Transl Lung Cancer Res; 2023 Jan; 12(1):127-140. PubMed ID: 36762057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study.
    Li X; Zhang Q; Lu Q; Cheng Z; Liu F; Han Z; Yu X; Yu J; Liang P
    Front Immunol; 2022; 13():1023983. PubMed ID: 36389778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.